Inflammation biomarkers and pathways
Inflammation biomarkers and pathways is a research topic within Immunology. Science Explorer counts 8.4k research works in it since 1959. 16.5% of them reached the world's top 10% most cited for their field and year.
This cluster of papers explores the role of triggering receptor expressed on myeloid cells-1 (TREM-1) and endocan in inflammatory responses, sepsis, and various inflammatory diseases. It investigates their impact on immune cells such as macrophages and neutrophils, as well as their potential as diagnostic markers for conditions like pneumonia and septic shock.
- TREM-1
- Endocan
- Inflammation
- Sepsis
- Macrophages
- Neutrophils
- Endothelial Cells
- Immune Response
- Diagnostic Marker
- Inflammatory Diseases
- Research works
- 8.4k fractional, since 1959
- In the world top 10%
- 1.4k per year above
- Top-10% rate
- 16.5% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +27% the tick is no change
Which countries lead Inflammation biomarkers and pathways research?
By volume, China and the United States publish the most (1k and 264 works in 2022–2025).
By volume, 2022–2025
- 1 China 1k works
- 2 United States 264 works
- 3 Türkiye 103 works
- 4 United Kingdom 56 works
- 5 India 55 works
- 6 Germany 51 works
- 7 Japan 46 works
- 8 Italy 37 works
- 9 Egypt 34 works
- 10 Indonesia 34 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Inflammation biomarkers and pathways research?
By volume in 2022–2025, Capital Medical University publishes the most Inflammation biomarkers and pathways research, followed by Central South University and Nanjing Medical University.
By volume, 2022–2025
- 1 Capital Medical UniversityChina 16 works
- 2 Central South UniversityChina 14 works
- 3 Nanjing Medical UniversityChina 13 works
- 4 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 13 works
- 5 Sun Yat-sen UniversityChina 11 works
- 6 Wenzhou Medical UniversityChina 10 works
- 7 Huazhong University of Science and TechnologyChina 9 works
- 8 Soochow UniversityChina 9 works
- 9 Xuzhou Medical CollegeChina 9 works
- 10 Washington University in St. LouisUnited States 8 works
Who are the leading researchers in Inflammation biomarkers and pathways?
The most-cited researchers publishing on Inflammation biomarkers and pathways include John Hardy, Henrik Zetterberg and David M. Holtzman.
- 1 John Hardy United Kingdom 4k citations
- 2 Henrik Zetterberg Sweden 3.1k citations
- 3 David M. Holtzman United States 2.8k citations
- 4 Ronit Katz United States 2.5k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Inflammation biomarkers and pathways research done?
The largest centres of Inflammation biomarkers and pathways research in 2022–2025 are Beijing (China), Shanghai (China), Guangzhou (China) and Nanjing (China).
Where is the best place to study Inflammation biomarkers and pathways?
Among universities, judged by research, Capital Medical University, Washington University in St. Louis and Nanjing Medical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Capital Medical UniversityChina | 56.4 | 25.4% | 13.8× | 16 | +50.7% |
| 2 | Washington University in St. LouisUnited States | 56.3 | 52.0% | 5.6× | 8 | +64.5% |
| 3 | Nanjing Medical UniversityChina | 51.5 | 25.3% | 13.0× | 13 | +84.7% |
| 4 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 48.3 | 29.2% | 6.5× | 13 | +101.4% |
| 5 | Central South UniversityChina | 43.8 | 31.2% | 4.1× | 14 | +66.1% |
| 6 | Huazhong University of Science and TechnologyChina | 38.5 | 41.9% | 2.9× | 9 | +76.6% |
| 7 | Wenzhou Medical UniversityChina | 37.0 | 26.2% | 13.6× | 10 | +18.8% |
| 8 | Xuzhou Medical CollegeChina | 31.9 | 22.7% | 20.1× | 9 | +66.2% |
| 9 | Shanghai Jiao Tong UniversityChina | 31.9 | 29.4% | 1.8× | 8 | +227.4% |
| 10 | Soochow UniversityChina | 29.5 | 27.6% | 5.5× | 9 | +50.5% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Inflammation biomarkers and pathways research growing?
Output in 2018–2022 was 27% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Inflammation biomarkers and pathways.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.